The Delhi High Court has rejected the claim of Novartis seeking injunction against Natco Pharma from manufacturing a cancer drug. The Court held that there can be no claim for infringement with respect to a patent which has been revoked in a post-grant proceedings. In the present case, Novartis AG had filed a petition seeking permanent injunction, damages, rendition of accounts and delivery...